Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew D Hellmann

Showing results (21-30 of 172) with videos related to

Pageof 18
Sort By:
JAMA Dermatology|December 13, 2018
Clinical Characterization of Immunotherapy-Related Pruritus Among Patients Seen in 2 Oncodermatology ClinicsGregory S Phillips, Azael Freites-Martinez, Jennifer Wu, et al.
Clinical Lung Cancer|May 25, 2015
Preliminary Safety, Pharmacokinetics, and Efficacy of Regorafenib, Cisplatin, and Pemetrexed in Patients With Advanced Nonsquamous Non-Small-Cell Lung CancersMatthew D Hellmann, Isrid Sturm, Zuzana Jirakova Trnkova, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 19, 2014
Clinical and in vivo evidence that EGFR S768I mutant lung adenocarcinomas are sensitive to erlotinibMatthew D Hellmann, Boris Reva, Helena Yu, et al.
IEEE Transactions on Medical Imaging|July 25, 2018
Multiple Resolution Residually Connected Feature Streams for Automatic Lung Tumor Segmentation From CT ImagesJue Jiang, Yu-Chi Hu, Chia-Ju Liu, et al.
Cancer|March 18, 2015
Differences in the survival of patients with recurrent versus de novo metastatic KRAS-mutant and EGFR-mutant lung adenocarcinomasHelena A Yu, Camelia S Sima, Matthew D Hellmann, et al.
Journal for Immunotherapy of Cancer|November 22, 2018
Acquired resistance to immunotherapy in MMR-D pancreatic cancerZishuo Ian Hu, Matthew D Hellmann, Jedd D Wolchok, et al.
Lung Cancer (Amsterdam, Netherlands)|June 20, 2017
Prognostic impact of TTF-1 expression in patients with stage IV lung adenocarcinomasJuliana B Schilsky, Ai Ni, Linda Ahn, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|December 2, 2019
Utilization and factors precluding the initiation of consolidative durvalumab in unresectable stage III non-small cell lung cancerNarek Shaverdian, Michael D Offin, Andreas Rimner, et al.
Immunity|January 5, 2022
Germline HLA landscape does not predict efficacy of pembrolizumab monotherapy across solid tumor typesAparna Chhibber, Lingkang Huang, Hong Zhang, et al.
Cancer Immunology Research|December 14, 2016
Somatic Mutations and Neoepitope Homology in Melanomas Treated with CTLA-4 BlockadeTavi Nathanson, Arun Ahuja, Alexander Rubinsteyn, et al.
Pageof 18

Showing results (21-30 of 172) with videos related to

Sort By:
Pageof 18
JAMA Dermatology|December 13, 2018
Clinical Characterization of Immunotherapy-Related Pruritus Among Patients Seen in 2 Oncodermatology ClinicsGregory S Phillips, Azael Freites-Martinez, Jennifer Wu, et al.
Clinical Lung Cancer|May 25, 2015
Preliminary Safety, Pharmacokinetics, and Efficacy of Regorafenib, Cisplatin, and Pemetrexed in Patients With Advanced Nonsquamous Non-Small-Cell Lung CancersMatthew D Hellmann, Isrid Sturm, Zuzana Jirakova Trnkova, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 19, 2014
Clinical and in vivo evidence that EGFR S768I mutant lung adenocarcinomas are sensitive to erlotinibMatthew D Hellmann, Boris Reva, Helena Yu, et al.
IEEE Transactions on Medical Imaging|July 25, 2018
Multiple Resolution Residually Connected Feature Streams for Automatic Lung Tumor Segmentation From CT ImagesJue Jiang, Yu-Chi Hu, Chia-Ju Liu, et al.
Cancer|March 18, 2015
Differences in the survival of patients with recurrent versus de novo metastatic KRAS-mutant and EGFR-mutant lung adenocarcinomasHelena A Yu, Camelia S Sima, Matthew D Hellmann, et al.
Journal for Immunotherapy of Cancer|November 22, 2018
Acquired resistance to immunotherapy in MMR-D pancreatic cancerZishuo Ian Hu, Matthew D Hellmann, Jedd D Wolchok, et al.
Lung Cancer (Amsterdam, Netherlands)|June 20, 2017
Prognostic impact of TTF-1 expression in patients with stage IV lung adenocarcinomasJuliana B Schilsky, Ai Ni, Linda Ahn, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|December 2, 2019
Utilization and factors precluding the initiation of consolidative durvalumab in unresectable stage III non-small cell lung cancerNarek Shaverdian, Michael D Offin, Andreas Rimner, et al.
Immunity|January 5, 2022
Germline HLA landscape does not predict efficacy of pembrolizumab monotherapy across solid tumor typesAparna Chhibber, Lingkang Huang, Hong Zhang, et al.
Cancer Immunology Research|December 14, 2016
Somatic Mutations and Neoepitope Homology in Melanomas Treated with CTLA-4 BlockadeTavi Nathanson, Arun Ahuja, Alexander Rubinsteyn, et al.
Pageof 18